Chegg, Inc. Form 8-K Summary
Business Context and Reporting Period
Chegg, Inc. (NYSE: CHGG) filed this Current Report on Form 8-K on April 1, 2025, regarding a notice received from the New York Stock Exchange (NYSE). The report addresses a failure to meet continued listing standards related to the company's minimum share price.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed is the stock price performance:
- Average Closing Share Price: Less than $1.00 over a consecutive 30 trading-day period ending March 31, 2025.
Material Changes
The material change reported is the receipt of a formal notice from the NYSE on April 1, 2025, stating non-compliance with Section 802.01C of the NYSE Listed Company Manual due to the low share price. This triggers a six-month cure period to regain compliance.
Outlook, Management Commentary, and Risks
Management Plan: The Company intends to notify the NYSE of its intent to regain compliance. Options being evaluated include effecting a reverse stock split, subject to board and stockholder approval. The Company will monitor the share price throughout the cure period.
Compliance Timeline: The Company has six months from the date of the notice to regain compliance. Compliance is achieved if, on the last trading day of any calendar month during this period, the closing share price is at least $1.00 and the 30-day average closing price is at least $1.00.
Risks and Contingencies:
- If the Company fails to regain compliance within the cure period, its common stock will be subject to suspension and delisting procedures.
- Forward-looking statements regarding the ability to regain compliance are subject to risks, including market reactions and the outcome of strategic alternatives.
- The notice has no immediate impact on the listing; the stock will continue to trade on the NYSE during the cure period.
Investor Verification Checklist
- Verify the current trading price of CHGG to assess the likelihood of regaining the $1.00 threshold organically.
- Monitor upcoming board meetings for announcements regarding a potential reverse stock split.
- Review the Company's Annual Report on Form 10-K for the year ended December 31, 2024, for detailed risk factors.
- Track the 30-day average closing price at the end of each calendar month during the six-month cure period.